[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Campania Luigi Vanvitelli\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":540},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,48,76,113,137,171,196,223,252,273,302,330,351,379,408,428,459,486,510],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100639040","personalized-robotic-telerehabilitation-for-upper-limb-functional-recovery-after-stroke-in-a-home-based-setting-100639040",false,"NCT07590349","Personalized Robotic Telerehabilitation for Upper Limb Functional Recovery After Stroke in a Home-Based Setting","ROBOHOME","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of stroke with residual upper-limb motor impairment\n* Upper-limb functional impairment defined by a Fugl-Meyer Assessment for Upper Extremity (FMA-UE) score between 20 and 50\n* Ability to understand study procedures and provide written informed consent\n* Availability of a home environment suitable for telerehabilitation\n\nExclusion Criteria:\n\n* Presence of severe neurological or musculoskeletal disorders affecting the upper limb\n* Severe spasticity (Modified Ashworth Scale ≥3)\n* Severe upper-limb pain (Numerical Rating Scale \\>4)\n* Skin lesions, infections, or conditions preventing safe use of wearable devices\n* Participation in another interventional clinical trial\n* Any medical or cognitive condition that may interfere with compliance or safe participation in the study","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"NA","Stroke is a leading cause of long-term disability worldwide, with upper-limb impairment representing a major determinant of functional limitation and reduced independence. Conventional rehabilitation approaches are often limited by accessibility, intensity, and long-term adherence, highlighting the need for innovative, home-based solutions.\n\nThis study aims to evaluate the effectiveness of a personalized robotic telerehabilitation program for upper-limb recovery in individuals with post-stroke motor impairment. The intervention combines a wearable robotic device with a virtual reality-based platform, enabling patients to perform structured, task-oriented exercises in a home environment under remote supervision.\n\nParticipants will be allocated to either a robotic-assisted telerehabilitation program or a control condition based on virtual reality-based rehabilitation alone. Motor recovery will be assessed using standardized clinical scales, including the Fugl-Meyer Assessment for Upper Extremity (FMA-UE), along with measures of functional performance, patient-reported outcomes, and treatment adherence.\n\nBy integrating robotic assistance with telemedicine, this study seeks to enhance rehabilitation intensity, improve patient engagement, and facilitate continuity of care beyond traditional clinical settings. The results are expected to support the development of accessible, personalized rehabilitation pathways for individuals with stroke-related upper-limb disability.",[26,27,28,29,30],"Stroke","Hemiparesis","Upper Extremity Paresis","Motor Impairment","Rehabilitation",[32,33,34,35],"stroke","Robotics","Telerehabilitation","Hemiplegia","NOT_YET_RECRUITING","2026-05-14",{"date":39,"type":40},"2026-05-15","ACTUAL",{"date":42,"type":20},"2026-06-01",{"date":44,"type":20},"2027-05-30",{"name":46,"class":47},"University of Campania Luigi Vanvitelli","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100602527","prospective-study-comparing-two-classification-systems-for-second-degree-vaginal-tears-during-spontaneous-childbirth-to-assess-their-ability-to-predict-postpartum-complications-100602527","NCT07124676","Prospective Study Comparing Two Classification Systems for Second-degree Vaginal Tears During Spontaneous Childbirth to Assess Their Ability to Predict Postpartum Complications.","Prospective Observational Study Comparing Two Classifications of Second-degree Perineal Tears in Spontaneous Vaginal Births, to Evaluate Their Correlation With Postpartum Clinical Outcomes.","LAC-VAG-2025","Inclusion Criteria:\n\n* Female at birth\n* Age ≥ 18 years\n* Spontaneous vaginal delivery\n* Presence of a spontaneous second-degree perineal tear confirmed on -postpartum examination\n* Ability and willingness to provide informed consent\n\nExclusion Criteria:\n\n* Obstetric or medical conditions preventing spontaneous vaginal delivery\n* Inability to understand study procedures or complete follow-up assessments","FEMALE",{"count":58,"type":20},482,"OBSERVATIONAL","The goal of this observational study is to learn whether different classification systems for second-degree perineal tears can predict postpartum complications in women undergoing spontaneous vaginal childbirth. The main questions it aims to answer are:\n\nDoes the Scandinavian classification better predict postpartum complications such as hemoglobin drop, perineal pain, occult muscle injury, and sexual dysfunction? Does the De Simone classification better correlate with these same postpartum outcomes?\n\nResearchers will compare the Scandinavian classification and the De Simone classification to see which system more accurately predicts clinically relevant postpartum complications.\n\nParticipants will:\n\nUndergo standard clinical assessment after spontaneous vaginal delivery with a second-degree perineal tear Have their perineal tear classified using both the Scandinavian and De Simone systems Receive routine postpartum evaluation, including hemoglobin measurement, pain assessment (VAS), and perineal ultrasound Complete follow-up assessment of sexual function using the Female Sexual Function Index (FSFI)",[62],"Vaginal Laceration During Delivery",[64,65],"vaginal laceration","delivery","RECRUITING","2026-04-22",{"date":69,"type":40},"2026-04-28",{"date":71,"type":40},"2025-11-04",{"date":73,"type":20},"2028-10-01",{"name":46,"class":47},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":97,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":75},"100567470","a-multifocal-tdcs-eeg-protocol-for-improving-symptoms-of-mild-cognitive-impairment-and-early-dementia-100567470","NCT06668610","A Multifocal tDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia","An Integrated Multifocal tDCS-EEG Protocol for Improving Cognitive and Affective Symptoms in Mild Cognitive Impairment and Early Stages of Dementia: a Crossover Double-blind Randomised Controlled Trial","MuSt-MID","Inclusion Criteria:\n\n* age between 55 and 85 years;\n* diagnosis of minor neurocognitive disorder, or major neurocognitive disorder with mild severity, according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5; APA 2013) with a Clinical Dementia Rating Scale (CDR) of .05 or 1 (Morris, 1993);\n* right handedness.\n\nExclusion Criteria:\n\n* brain events with an acute aetiology (stroke, traumatic brain injury, neoplastic ablation);\n* psychiatric disorders (schizophrenia, psychosis, bipolar disorder) and assumption of psychotropic drugs;\n* diagnosis of moderate or severe major neurocognitive disorders (DSM-5; APA 2013) with CDR scores equal or above 2 (Morris, 1993);\n* any condition with may also hypothetically interfere with electrophysiological recording and neurostimulation (metallic implants in the brain, cochlear implant, pacemakers, or suffering from epilepsy) (Antal et al., 2017; Bikson et al., 2016).","55 Years","85 Years",{"count":87,"type":20},50,[23],"The goal of this clinical trial is to learn if an integrated protocol using multifocal non invasive brain stimulation and brain recording combined with cognitive training is effective in treating cognitive and affective symptomatology in patients with mild cognitive impairment and early stages of dementia. The main questions it aims to answer are:\n\n* Does multifocal non-invasive brain stimulation reduce cognitive and affective symptoms in patients with mild cognitive impairment and early stages of dementia?\n* Do some specific factors, such as education and cognitive reserve, affect the extent of the possible outcomes achievable from the intervention?\n* Do electrophysiological measures contribute identifying responders and non-responders to the treatment? Researchers will compare real non-invasive brain stimulation to a placebo stimulation (reproducing the same feeling of stimulation without actually stimulating the brain) combined with cognitive rehabilitation on general cognition measures and depression symptoms.\n\nParticipants will\n\n* Undergo two treatment cycles (real stimulation or placebo over frontal and temporal ares of the left hemisphere) combined with cognitive training twice a week for two months.\n* Complete neuropsychological evaluations before the first rehabilitation cycle and at the end of each rehabilitation cycle.\n\nCaregivers will provide information on functional daily living activities for their relatives.",[91,92,93,94,95,96],"Mild Cognitive Impairment (MCI)","Dementia","Alzheimer Disease, Early Onset","Alzheimer Disease","Frontotemporal Degeneration (FTD)","Neurocognitive Decline",[98,99,100,101,102,103,104,105],"non invasive brain stimulation (NIBS)","transcranial direct current stimulation (tDCS)","electroencephalography (EEG)","crossover","randomised controlled trial","mild cognitive impairment","early stage dementia","multifocal brain stimulation","2026-04-21",{"date":67,"type":40},{"date":109,"type":40},"2024-10-01",{"date":111,"type":20},"2026-10-01",{"name":46,"class":47},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},"100622872","phase-3-continuation-of-cetuximab-beyond-first-line-progression-in-metastatic-colorectal-cancer-100622872","NCT07389265","Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","CAPRI-3 GOIM Study: Phase 3 Clinical Study to Evaluate the Use of Continuing Cetuximab Treatment Beyond First Line Progression in Molecular Selected Metastatic Colorectal Cancer Patients.","CAPRI-3 GOIM","Inclusion Criteria:\n\n1. Histologically proven diagnosis of colorectal adenocarcinoma.\n2. Diagnosis of metastatic disease.\n3. Efficacy of a first line therapy containing anti-EGFR drug with a major response achieved (i.e. complete or partial response according to RECIST criteria v1.1) or a prolonged (at least 6 months) stable disease.\n4. Progression to first line therapy.\n5. RAS and BRAF wild-type status of FFPE analysis of primary colorectal cancer and\u002For related metastasis.\n6. RAS (NRAS and KRAS exon 2,3 and 4), BRAFV600E, PIK3CA, EGFR ECD wild-type and HER2 not amplified in liquid biopsy at the time of screening (according to NGS, Foundation\u002FRoche).\n7. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST criteria, vers.1.1).\n8. Male or female patients ≥ 18 years of age.\n9. ECOG Performance Status 0-1.\n10. Adequate bone marrow, liver and renal function assessed within 14 days before starting study treatment as defined by the following parameters:\n\n    Bone marrow:\n    * Absolute Neutrophil Count (ANC) ≥ 1.5 x 109\u002FL\n    * Hemoglobin (Hgb) ≥ 9 g\u002FdL\n    * Platelets ≥ 100 x 109\u002FL\n\n    Liver function:\n\n    • Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]) and ALT (SGPT) ≤ 2.5 x ULN, except in patients with tumor involvement of the liver who must have AST and ALT ≤ 5 x ULN\n\n    Renal function:\n\n    • Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL\u002Fmin\n11. If female and of childbearing potential\\*, have a negative result on a pregnancy test performed a maximum of 7 days before initiation of study treatment.\n\n    \\*A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.\n12. If female and of childbearing potential, or if male, agreement to use adequate contraception (e.g., abstinence, intrauterine device, oral contraceptive, or double-barrier method), during the study and until at least 6 months after last dose of study treatment administration, based on the judgment of the Investigator or a designated associate.\n13. Signed informed consent obtained before screening.\n\nExclusion Criteria:\n\n1. Any contraindication to the use of cetuximab, bevacizumab, Irinotecan, 5-FU, oxaliplatin, folic acid.\n2. Active uncontrolled infections, active disseminated intravascular coagulation or history of interstitial lung disease.\n3. Past or current history of malignancies other than colorectal carcinoma, except for curatively treated basal and squamous cell carcinoma of the skin cancer or in situ carcinoma of the cervix.\n4. Pregnancy (exclusion to be ascertained by a beta hCG test).\n5. Breastfeeding.\n6. Fertile women (\\\u003C2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception.\n7. Myocardial infarction, unstable angina pectoris, balloon angioplasty (PTCA) with or without stenting within the past 12 months before inclusion in the study, Grade III or IV heart failure (NYHA classification).\n8. Cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta blockers or digoxin.\n9. Medical or psychological impairments associated with restricted ability to give consent or not allowing conduct of the study.\n10. Participation in a clinical study or experimental drug treatment within 30 days prior to study inclusion or during participation in the study.\n11. Known or clinically suspected brain metastases.\n12. History of acute or subacute intestinal occlusion or chronic inflammatory bowel disease or chronic diarrhea.\n13. Severe, non-healing wounds, ulcers or bone fractures.\n14. Marked proteinuria (nephrotic syndrome).\n15. Known DPD deficiency (specific screening not required).\n16. Known history of alcohol or drug abuse.\n17. A significant concomitant disease which, in the investigating physician's opinion, rules out the patient's participation in the study.\n18. Absent or restricted legal capacity.\n19. Patients with known dMMR or MSI-H tumors who are eligible for approved immune checkpoint inhibitor therapy will be excluded from the trial, unless ICI therapy is contraindicated or declined by the patient. This ensures alignment with current standard of care.",{"count":122,"type":20},480,[124],"PHASE3","The goal of this Phase 3 clinical trial is to evaluate whether continuing cetuximab treatment beyond first-line progression can improve outcomes in patients with metastatic colorectal cancer whose tumors are RAS and BRAF wild-type. The study will compare the effectiveness of chemotherapy given together with cetuximab versus chemotherapy given together with bevacizumab. Researchers aim to determine whether cetuximab continuation improves tumor response, progression-free survival, overall survival, and safety in this patient population.\n\nEligible participants are adults with metastatic colorectal cancer who have previously responded to first-line treatment with chemotherapy combined with an anti-EGFR antibody. Before starting therapy, patients will undergo molecular testing using liquid biopsy to confirm tumor characteristics. They will then receive chemotherapy with either cetuximab or bevacizumab every two weeks, and their disease will be monitored regularly with CT or MRI scans, laboratory tests, and clinical evaluations. During the study, patients will also provide biological samples for translational research.\n\nThis trial will enroll about 360 patients across sites in Italy and Spain and is designed to provide new evidence on whether cetuximab continuation beyond first-line treatment can offer a meaningful clinical benefit compared with standard therapy.",[127],"Metastatic Colorectal Cancer (mCRC)","2026-02-04",{"date":130,"type":40},"2026-02-05",{"date":132,"type":40},"2025-10-01",{"date":134,"type":20},"2030-10",{"name":46,"class":47},41,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":145,"sex":16,"minAge":17,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":75},"100571299","tinnitus-and-treatment-with-umpea-lut-100571299","NCT06718452","Tinnitus and Treatment With umPEA-LUT","Treatment of Tinnitus Targeting Neuroinflammation. umPEALUT as Possible Option","TiniPEA","Inclusion Criteria:\n\n\\- Patients with tinnitus not under treatment at least for 30 days\n\nExclusion Criteria:\n\n* Stroke in the last year\n* Uncontrolled diabetes,\n* Uncontrolled hypertension,\n* Severe psychiatric disorders,\n* Severe cognitive decline,\n* Previous surgery of the brain or audio-vestibular nerves",true,"70 Years",{"count":148,"type":20},100,[23],"Tinnitus can have different causes. From a peripheral point of view, the sensation of hearing a not present sound can be indicative of damage in the cells of the cochlea. Damage at this level can arise from traumatic, vascular, toxic origins or be caused by systemic pathologies. However, all the previous causes have a common denominator, the presence of reactive oxygen species (ROS), in the cochlea which determines the damage and the consequent death of the hair cells into the ear. The sound (tinnitus) that the patient perceives is generated by the spontaneous movement of the cilia of the hair cells; this phenomenon arises when these cells begin to be damaged.\n\nTinnitus can be also caused by a retrocochlear disorder such as damage of the auditory nerve (inflammatory and tumor cause). In case of an inflammatory origin, the factors released during inflammation can locally damage the nerves and spread into the cochlea destroying the hair cells.\n\nTinnitus can also originate from damage in the central auditory pathway. In this case, the problem persistent. It is important to keep in mind that although initially the tinnitus may originate from a damage inside the cochlea, after 6 months of persistence chronicizes causing an activation (without stimulus) of the upper auditory areas. This zone of \"hypersensitivity\" is therefore responsible for chronic tinnitus.\n\nIn addition to the overmentioned medical causes, tinnitus can also be sign of psychiatric\u002Fpsychological disorders, in those cases in whom there is an involvement of the hypothalamus, as showed by neuropsychological studies. Tinnitus can be temporary and disappear spontaneously or, in the most of cases, be persistent and extremely annoying\u002Fstressful for the patient. At night in particular, in the absence of noise, the patient suffers more the presence of this ghost sound, which in some occasions prevents sleep. Insomnia negatively impacts on tinnitus increasing its duration and intensity, thus establishing a perpetual cycle of stress into the brain. The latter phenomenon worses and chronicizes the symptom .\n\nStress causes inflammation with ROS increase, which can affect both the peripheral and central auditory pathways. Recently, it has been shown that tinnitus can be a symptom of neuro-inflammatory pathologies such as, for example, Multiple Sclerosis.\n\nThe effects of inflammation on the hair cells are identifiable only through electrophysiological studies or from the temporal bone.\n\nKeeping on mind inflammation and neuro-inflammation and considering the exchange between cerebrospinal fluid and perilymph , we speculate that the use of a molecule capable of reducing inflammation and modulating the action of mast cells and microglia, could be an effective tool to resolve tinnitus; moreover, thanks to its powerful action at the level of neuro-inflammation, it could reduce the hyper-activity in the upper auditory tracts, thus reducing\u002Fabolishing noise.\n\numPeaLut combines palmitoylethanolamide, which modulates the activity of mast cells, macrophages and microglia and luteolin, a bioflanoid extracted from fruits with anti-oxidant properties, able to improve microcirculation. Because the alterations of the ear microcirculation can be an additional cause of tinnitus, we believe that luteolin content can be an ulterior benefit.\n\nAlthough various attempts have been made to use a mono-molecule, recent studies have shown that combination of several elements could reduce tinnitus ; PeaLut, in its ultra-micronized form with high bioavailability, could be the perfect solution.\n\nThis study aims at evaluating the efficacy of umPEALUT as a therapeutic treatment of tinnitus in a sample of adults.",[152,153],"Tinnitus","Neuroinflammation",[152,153,155,156,157,158,159,160,161,162],"Palmitoyetanolamide","Luteolin","Ultramicronized","Vascular","Central","Peripheral","Auditory cortex","Inner ear","2026-02-03",{"date":165,"type":40},"2026-02-06",{"date":167,"type":20},"2026-04-20",{"date":169,"type":20},"2026-12-31",{"name":46,"class":47},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":145,"sex":16,"minAge":17,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":75},"100594934","screening-for-postpartum-depression-using-epds-and-ham-d-in-mothers-within-72-hours-after-delivery-at-a-tertiary-care-center-sos-mamma-study-100594934","NCT07025902","Screening for Postpartum Depression Using EPDS and HAM-D in Mothers Within 72 Hours After Delivery at a Tertiary Care Center (SOS-Mamma Study)","Holistic Support Pathways for Maternal Psychological Wellbeing: A Comprehensive Approach From Preconception to Postpartum (SOS-Mamma).","SOS-Mamma","nclusion Criteria\n\nWomen aged ≥18 and \\\u003C45 years at the time of delivery\n\nSingleton pregnancy at term (≥37 weeks) or late preterm (≥35 weeks of gestation)\n\nLive-born infant in clinically stable condition at discharge\n\nAbility to understand and complete self-reported questionnaires (EPDS) in Italian or English\n\nAbility to provide written informed consent\n\nScreening performed within 72 hours postpartum during routine hospital stay\n\nExclusion Criteria\n\nMultiple pregnancy (e.g., twins or higher-order gestations)\n\nMajor psychiatric diagnosis under active treatment at the time of delivery (e.g., schizophrenia, bipolar disorder)\n\nSevere language barriers preventing adequate understanding of the consent form or questionnaires\n\nNeonatal death or congenital anomalies requiring prolonged NICU admission\n\nMaternal age \\\u003C18 or ≥45 years at delivery\n\nGestational age at birth \\\u003C35 weeks","45 Years",{"count":181,"type":20},273,"Postpartum depression (PPD) is one of the most common complications affecting maternal mental health after childbirth, with an estimated prevalence of 10-20% in high-income countries. Despite its frequency and the availability of effective screening tools, early diagnosis remains largely underestimated in routine clinical care.\n\nThis study, part of the national SOS-Mamma project funded by the Italian Ministry of Health, aims to systematically screen for signs of postpartum depression in women giving birth at a tertiary care obstetric unit (AOU Vanvitelli - UOC of Obstetrics and Gynecology, Naples, Italy). The goal is to promote early detection and timely referral to specialized care pathways.\n\nThe study is a prospective, observational, monocentric, non-interventional, non-pharmacological study. All eligible women who deliver at the hospital will be invited to participate within the first 72 hours after childbirth. Participants will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) - a widely used self-report questionnaire - and will undergo a brief clinical interview using the Hamilton Depression Rating Scale (HAM-D), conducted by trained healthcare staff.\n\nThe study's primary objective is to estimate the real-world incidence of postpartum depression within this population. Secondary objectives include identifying socio-demographic and obstetric risk factors associated with depressive symptoms, assessing the acceptability and feasibility of routine screening, and contributing to the development of a replicable model of care aligned with international recommendations (NICE, WHO, ISS).\n\nCollected data will be anonymized and analyzed to provide evidence on early indicators of PPD and guide improvements in clinical care. Women identified as being at risk (e.g., EPDS \\>10 or presence of suicidal ideation) will be referred to specialist psychiatric services in accordance with clinical guidelines.\n\nParticipation in the study is voluntary. All procedures comply with European data protection regulations and Good Clinical Practice (GCP) principles. No experimental treatments are involved, and no changes to standard care will be made based on study participation.\n\nBy highlighting the need for structured mental health screening in the postpartum period, this study hopes to improve maternal wellbeing and reduce the long-term impact of undiagnosed depression on mothers and their children.",[184],"Post Partum Depression",[184,186,187],"EPDS","HAM-D Scales","2025-06-17",{"date":190,"type":40},"2025-06-18",{"date":192,"type":20},"2025-07-15",{"date":194,"type":20},"2027-12-01",{"name":46,"class":47},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":145,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":206,"conditions":207,"keywords":210,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":4},"100584356","dna-methylation-in-brugada-syndrome-and-risk-of-sudden-cardiac-death-100584356","NCT06888271","DNA Methylation in Brugada Syndrome and Risk of Sudden Cardiac Death","DNA Methylation in Brugada Syndrome and Risk of Sudden Cardiac Death (ANDROMEDA)","ANDROMEDA","Inclusion Criteria:\n\n* Brugada syndrome was confirmed when the 12-lead ECG showed ST-segment elevation with a type-1 morphology of ≥2 mm in ≥1 right precordial lead either spontaneously or after a provocative drug test (intravenous administration of a Class I antiarrhythmic) in the absence of any structural heart disease.\n* \\>18 years\n* Unrelated patients\n\nExclusion Criteria:\n\n* Related patients\n* Not type 1 Br patter",{"count":205,"type":20},10,"The goal of this observational study is to evaluate if there are differences in DNA methylation of peripheral blood in patients with Brugada syndrome and healthy subjects. The main question it aims to answer is:\n\nDoes DNA methylation changes distinguish Brugada patients from healthy controls?\n\nDoes DNA methylation changes distinguish Brugada patients with high versus low risk of sudden cardiac death?",[208,209],"Brugada Syndrome","Sudden Cardiac Death Due to Cardiac Arrhythmia",[211,212,213,214],"DNA methylation","Liquid biopsy","Sudden cardiac death","Brugada syndrome","2025-03-20",{"date":217,"type":40},"2025-03-24",{"date":219,"type":20},"2025-05",{"date":221,"type":20},"2026-07",{"name":46,"class":47},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":145,"sex":16,"minAge":179,"maxAge":146,"enrollmentInfo":231,"targetDuration":4,"studyType":21,"phases":233,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":4},"100571511","mobile-app-use-for-physical-activity-in-knee-osteoarthritis-100571511","NCT06721208","Mobile App Use for Physical Activity in Knee Osteoarthritis","Development of a Mobile APP to Promote Physical Activity in Individuals With Knee Osteoarthritis: a \"Move for Knee\" Study Protocol","moveforknee","Inclusion Criteria:\n\n* Patients with unilateral or bilateral tibiofemoral osteoarthritis according to the American College of Rheumatology classification criteria for osteoarthritis, aged between 45 and 70 years, with radiographic findings (Kellgren-Lawrence grade 1-3)\n* Expression of consent to participate in the study through a signed informed consent form\n* Ability to understand and use the APP through a practical demonstration in an outpatient setting\n\nExclusion Criteria:\n\n* Psychiatric disorders that could potentially invalidate informed consent\n* Pregnancy or breastfeeding",{"count":232,"type":20},150,[23],"The goal of this clinical trial is to evaluate the effectiveness of an app developed to provide useful guidance on physical activity for people with knee osteoarthritis.The main question it aims to answer is:\n\n\"What physical activity can I perform with knee osteoarthritis?\" Researchers will compare use of app developed to provide physicial activity program versus educational advices (a look-alike substance that contains no drug) to see if APP works to treat pain and stiffness related to knee osteoarthritis.\n\nParticipants will:\n\nDownload and use APP Visit the clinic once every 4 weeks for checkups and tests",[236],"Knee Osteoarthristis",[238,239,240,241,242,243],"knee osteoarthiritis","physical activity","functioning","pain","digital health","mobile application","2025-02-06",{"date":246,"type":40},"2025-02-10",{"date":248,"type":20},"2025-05-02",{"date":250,"type":20},"2026-12-02",{"name":46,"class":47},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":259,"targetDuration":261,"studyType":59,"phases":4,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":4},"100557510","migrant-reflex-test-hdv-migred-project-100557510","NCT06539052","MIGrant Reflex Test HDV (MIGRED) Project","A Model to Improve the Screening and Linkage to Care of HDV Infection in Migrant Living in Southern Italy Taking Advantage of HDV Reflex Testing: MIGrant Reflex Test HDV (MIGRED) Project","Inclusion Criteria:\n\n* All migrants, documents or undocumented migrants, and low-income refugees belonging to the infectious disease centers of the university centers participating in the project will be enrolled. aged \\> 18 years subjects who have given informed consent to carry out blood sampling and for the collection of epidemiological data\n\nExclusion Criteria:\n\n* all migrants \\\u003C 18 years of age who have not given informed consent for the collection of the blood sample and\u002For epidemiological data.",{"count":260,"type":20},7500,"2 Months","Our research team has executed a robust strategy to improve viral hepatitis detection and linkage to care in migrants, contributing to the improvement of knowledge on the clinical and virological future of viral hepatitis in this population difficult to reach and manage. Our hypothesis is that the extension of our model to three other large university clinical centers operating in southern Italy and the use of HDV reflex testing for HBsAg-positive subjects will allow the implementation of knowledge on prevalence of HDV in migrants living in southern Italy and coming from HDV endemic areas. Precisely, the investigators will involve the Department of Infectious Diseases of the University of Bari, that of the University of Catanzaro and that of the University of Palermo with expertise in the management of infectious diseases in the migratory context and with whom the investigators have previously collaborated in other areas.\n\nIt is expected to enroll at least 7500 patients. The project will last 18 months.\n\nDiagnosis and treatment of HDV infection in migrants will reduce the circulation of HDV in low endemic regions such as our region. Follow-up of HDV-infected individuals and reducing the rate of new infections among migrants will reduce the number of people who will experience complications related to HDV infection, such as decompensated liver cirrhosis and carcinoma hepatocellular. All this will determine benefits for the Italian public health system.",[264],"Hepatitis D Virus Infection","2024-12-17",{"date":267,"type":40},"2024-12-18",{"date":269,"type":20},"2024-12-20",{"date":271,"type":20},"2026-12-20",{"name":46,"class":47},{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":21,"phases":284,"briefSummary":286,"conditions":287,"keywords":289,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":301},"100572893","phase-2-virtual-reality-for-cognitive-impairment-in-hemodialysis-100572893","NCT06739187","Virtual Reality for Cognitive Impairment in Hemodialysis","Virtual Reality Training for Cognitive Impairment in Adults Treated With Hemodialysis: A Feasibility Randomized Controlled Trial","VIRTUAL","Inclusion Criteria:\n\n* Adult participants aged 18 years or older and less than or equal to 75 years of age\n* Receiving haemodialysis treatment for kidney failure for at least 90 days (permanent reduction in kidney function below an estimated glomerular filtration rate of 15 mL\u002Fminute per 1.73 m2)\n* Able to provide written and informed consent\n* Able to use the immersive virtual reality headset and follow instructions with sufficient motor, visual and auditory function to interact with the intervention\n* Able to speak and understand Italian language\n\nExclusion Criteria:\n\n* Severe cognitive impairment or psychiatric diseases leading to inability to follow instructions and use the virtual reality headset\n* Significant nystagmus and\u002For vertigo leading to inability to tolerate the virtual reality headset\n* Insufficient motor function to use the virtual reality system\n* Hearing or visual disability\n* Advanced or uncompensated chronic diseases unrelated to kidney failure (e.g. advanced cancer, heart failure, lung diseases with poor oxygen saturation)\n* Other neurological diseases (ictus, Alzheimer's or other forms of dementia)\n* Persistent pain or itch or who using opioids that may interfere with the tests or any other condition that the clinician may judge as influencing the results","75 Years",{"count":283,"type":20},60,[285],"PHASE2","The goal of this randomized feasibility clinical trial is to identify participant recruitment and retention, acceptability, and adherence to virtual reality training in people undergoing hemodialysis. The main question it aims to answer is if virtual reality could be a feasible and acceptable intervention in this setting.\n\nThe investigators will compare participants on virtual reality training during the standard dialysis session with those treated with standard dialysis session alone to see if a cognitive training using immersive virtual reality in people on hemodialysis is feasible and acceptable.\n\nParticipants randomised in the intervention group will use virtual reality during the standard dialysis session for 30 minutes, three times a week for 12 weeks. The virtual reality intervention will consist of computerized cognitive training of 4 games. Each exercise delivered to the participant will specifically provide training in a specific cognitive category (memory, cognitive flexibility, processing, attention, and memory). Participants randomised in the control group will perform the standard hemodialysis session three times a week for 12 weeks, without using virtual reality.",[288],"Hemodialysis",[290,291,292,293],"hemodialysis","virtual reality","RCT","kidney failure","2024-12-12",{"date":267,"type":40},{"date":297,"type":20},"2025-04-01",{"date":299,"type":20},"2026-04-01",{"name":46,"class":47},2,{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":145,"sex":16,"minAge":309,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":21,"phases":313,"briefSummary":314,"conditions":315,"keywords":319,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":75},"100568729","evaluation-of-dental-and-periodontal-health-after-ipr-in-patients-in-orthodontic-treatment-with-clear-aligners-100568729","NCT06685016","Evaluation of Dental and Periodontal Health After IPR in Patients in Orthodontic Treatment With Clear Aligners","Evaluation of Dental and Periodontal Health After Interproximal Enamel Reduction, in Patients in Orthodontic Treatment With Clear Aligners, and Comparison Between Laser Diode and Sodium Fluoride for the Treatment of Dentin Hypersensitivity","Inclusion Criteria:\n\n* to be in orthodontic treatment with clear aligners and this treatment requires interproximal enamel reduction;\n* permanent dentition;\n* good oral and periodontal health.\n\nExclusion Criteria:\n\n* enamel defects;\n* cervical caries;\n* periodontal disease;\n* history of trauma or craniofacial anomalies;\n* pregnancy.","17 Years","100 Years",{"count":312,"type":20},30,[23],"This study aimed to evaluate dental and periodontal health after interproximal enamel reduction and to compare Laser diode (a device used in the Orthodontic Program) and sodium fluoride (often used in the Orthodontic Program and in the Material Dental Program). The hypothesis was that the intervention groups would show a lower dentin hypersensitivity incidence than the control group during orthodontic treatment.",[316,317,318],"Dentinal Hypersensitivity","Plaque, Dental","Bleeding Gum",[320,321],"Clear Aligners","Interproximal enamel reduction","2024-11-12",{"date":324,"type":40},"2024-11-14",{"date":326,"type":40},"2023-06-24",{"date":328,"type":20},"2024-12",{"name":46,"class":47},{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":75},"100560887","dna-methylation-trajectories-in-aging-100560887","NCT06582992","DNA Methylation Trajectories in Aging","EPIGENETIC-SENSITIVE BIOMARKERS OF INFLAMMAGING FROM HEALTHY TO HEART FAILURE DISEASE","EPI-GERAS","Inclusion Criteria:\n\n* Healthy subjects aged between 18 and 40 years\n* Aged subjects (≥65) without signs and symptoms of heart failure\n* Aged subjects (≥65) with diagnosis of heart failure with preserved ejection fraction (EF major than 50%)\n\nExclusion Criteria:\n\n* Heart failure with reduced ejection fraction (EF minor than 40%)\n* Heart failure with mildly reduced EF (HFmrEF) (EF 41-49%)\n* History or diagnosis of cancer and inflammatory diseases",{"count":232,"type":20},"The goal of this observational study is to profile changes in DNA methylation of circulating CD4+ T and CD8+ T cells from healthy young to aged with diagnosis of HFpEF, a particular phenotype of HF which is highly prevalent in aging.\n\nThe main question it aims to answer is:\n\n-Do DNA methylation biomarkers help us to understand the role of inflammation in HFpEF during aging?\n\nOur goal is to provide a simple large-scale panel of epigenetic-sensitive biomarkers useful in aged patients with HF in the early natural history of the disease (HFpEF).",[341,342],"Heart Failure","Aging","2024-08-31",{"date":345,"type":40},"2024-09-03",{"date":347,"type":20},"2024-11",{"date":349,"type":20},"2025-11",{"name":46,"class":47},{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":358,"enrollmentInfo":359,"targetDuration":4,"studyType":21,"phases":360,"briefSummary":361,"conditions":362,"keywords":366,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":378},"100559404","continuous-glucose-monitoring-in-hie-100559404","NCT06563687","Continuous Glucose Monitoring in HIE","Real-time Continuous Glucose Monitoring in Infants With Hypoxic-ischaemic Encephalopathy: a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Birth weight \\>1.8kg\n* Gestation \\>35 weeks\n* Aged \\\u003C6hours\n* Moderate or severe HIE following perinatal asphyxia\n\nExclusion Criteria:\n\n* Major congenital malformations\n* Inborn errors of metabolism,\n* Congenital infections\n* Imminent death","6 Hours",{"count":19,"type":20},[23],"The aim of the study is to examine whether the use of continuous glucose monitoring (CGM) to guide the clinical management of glycaemic control will result into an increased time in the target glucose concentration. To further examine the efficacy of using CGM the following secondary outcomes in the two groups were assessed: mean glucose values, glucose variability within individuals, percentage of time that glucose values are in hyperglycaemic or hypoglycaemic ranges.\n\nRandomized controlled trial recruiting neonates (Birth weight \\>1.8kg, Gestation\\>36 weeks) with moderate or severe hypoxic ischemic encephalopathy (HIE) following perinatal asphyxia . Neonates will be randomly assigned (1:1) within 6 hours of birth to receive either the intervention with real-time CGM or standard care for 72 hours.",[363,364,365],"Hypoxic Ischemic Encephalopathy of Newborn","Hyperglycemia","Hypoglycemia",[367,368,369],"Continuous glucose monitoring","Neonatal hypoglycemia","Neonatal hyperglycemia","2024-08-20",{"date":372,"type":40},"2024-08-21",{"date":374,"type":40},"2024-08-01",{"date":376,"type":20},"2026-12-01",{"name":46,"class":47},3,{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":388,"conditions":389,"keywords":391,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":75},"100553238","environmental-pollutants-in-copd-and-lung-cancer-100553238","NCT06483490","Environmental Pollutants in COPD and Lung Cancer","Mitochondrial Dysfunction and Immune Checkpoints in Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer: the Role of Environmental Pollutants","Inclusion Criteria:\n\n* All patients of both sexes and over the age of 18 years\n* Clinical diagnosis of suspected lung cancer\n\nExclusion Criteria:\n\n* Patients with infectious diseases,\n* Patients with interstitiopathy\n* Patients with autoimmune diseases\n* Patients with cancers not covered by the inclusion criteria\n* subjects on glucocorticoid therapy\n* subjects who cannot undergo bronchial biopsy\n* subjects who will not sign informed consent.",{"count":387,"type":20},200,"Epidemiological studies describe a statistically significant correlation between hospitalization rate and exposure to environmental pollutants such as atmospheric particulates (PM10 and PM2.5) and polycyclic aromatic hydrocarbons (PAH). Indeed, they induced the release of inflammation mediators and oxidative stress, involved in remodeling and destruction of the alveolar parenchyma, in turn associated with the respiratory disease onset and progression such as asthma, COPD, pulmonary fibrosis and lung cancer. Interestingly, oxidative stress associated with environmental pollutants could also induce DNA damage by affecting the stability of G-quadruplex (G4) sequences. Given the role of G4 in physiological and pathological processes and their presence in mitochondrial DNA, telomeres and proto-oncogene promoters, it is interesting to investigate the potential involvement in cellular mechanisms of response to oxidative stress associated with pollutants. Moreover, it is known that pollutant-induced oxidative stress has the ability to alter mitochondrial integrity, leading to mitochondrial dysfunction. The mitochondria involvement in the innate and adaptive immune response regulation corroborates the role of pollutants in respiratory diseases pathogenesis. Indeed, mitochondrial function and integrity are critical for both the effector and memory stages of differentiation of T cells which play a primary role in respiratory diseases. In this context, the PD-1\u002FPD-L1 immune check-points are essential in promoting the immune system homeostasis. Currently, although the role of environmental pollutants, mitochondrial dysfunction and the PD-1\u002FPD-L1 axis in the pathogenesis of many respiratory diseases is recognized, it is useful to further clarify the underlying molecular interconnections and the mechanisms by which pollutants could affect mitochondrial integrity and immune checkpoints.",[390],"COPD and Lung Cancer",[392,393,394,395,396,397,398,399],"COPD","Lung cancer","Mitochondrial dysfunction","immune checkpoints","Environmental pollution","cross-sectional","non-pharmacological","multicenter study","2024-06-25",{"date":402,"type":40},"2024-07-03",{"date":404,"type":40},"2023-05-01",{"date":406,"type":20},"2026-05-01",{"name":46,"class":47},{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":179,"enrollmentInfo":415,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":75},"100552246","superficial-and-deep-endometriosis-role-of-systemic-inflammation-as-a-marker-of-clinical-surgical-and-reproductive-outcomes-100552246","NCT06470594","Superficial and Deep Endometriosis: Role of Systemic Inflammation as a Marker of Clinical, Surgical, and Reproductive Outcomes","ESPRIMO-CCR","Inclusion Criteria:\n\n* Age between 18 and 45 years.\n* Postoperative follow-up of at least 12 months;\n* Signature of informed consent regarding laparoscopic surgical treatment.\n* Signature of informed consent to the processing of personal data duly documented by medical records.\n\nExclusion Criteria:\n\n* Failure to sign informed consent for laparoscopic surgical treatment\n* Histologic diagnosis of borderline tumor and\u002For ovarian carcinoma and\u002For mucinous cystadenoma and\u002For germ cell tumor or other malignancy of the genital tract\n* postoperative follow-up of less than 12 months;\n* documented history of inflammatory, rheumatologic, or immunologic disease; and\n* failure to provide informed consent for personal data processing.",{"count":416,"type":20},138,"Primary aim of this study is to evaluate the change in systemic inflammation parameters after surgery for superficial, ovarian or deep endometriosis. Secondary objectives focus on correlating these parameters to clinical outcomes, in patients with pelvic pain, and reproductive outcomes, in women desiring offspring.\n\nParticipants already scheduled for surgery as part of their endometriosis care will be followed regarding the abovementioned outcomes after calculation of pre and postsurgical systemic inflammation markers (neutrophil to lymphocyte ratio; platelet to lymphocyte ratio and lymphocyte to monocyte ratio)",[419],"Endometriosis","2024-06-17",{"date":422,"type":40},"2024-06-24",{"date":424,"type":40},"2024-05-29",{"date":426,"type":20},"2026-06",{"name":46,"class":47},{"id":429,"slug":430,"hasResults":11,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":434,"eligibilityCriteria":435,"healthyVolunteers":11,"sex":16,"minAge":436,"maxAge":437,"enrollmentInfo":438,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":440,"conditions":441,"keywords":444,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":458},"100545463","the-pro-future-project-100545463","NCT06382233","The PRO-FUTURE Project","PRecocious biOmarkers oF Unilateral ureTero-pelvic jUnction obstRuction in childrEn","PRO-FUTURE","Inclusion Criteria:\n\n* unilateral UPJO\n* 0-5years of age\n\nExclusion Criteria:\n\n* bilateral UPJO\n* previous surgical intervention on the urinary tract\n* bladder or lower urinary tract symptoms or malformations\n* nephro- or urolithiasis, vesicoureteral reflux\n* urinary tract infections.","1 Day","5 Years",{"count":439,"type":20},85,"The goal of this observational study is to learn about specific biomarkers of unilateral ureteropelvic junction obstruction (UPJO) in children undergoing surgical intervention for unilateral UPJO compared with controls. The main question it aims to answer are:\n\n* Are Urinary single-cell and extracellular vesicles (EVs) screening useful to stage the intrarenal injury and repair processes in UPJO babies?\n* Do babies with unilateral UPJO have a whole blood gene expression profiling (WBGEP) allowing an accurate unilateral UPJO diagnosis?",[442,443],"Ureteropelvic Junction Obstruction","Chronic Kidney Diseases",[445,446,447,448,449],"Ureteropelvic junction obstruction","Biomarkers","Single-Cell","Extracellular vesicles","Congenital anomalies of the kidney and urinary tract","2024-04-26",{"date":452,"type":40},"2024-04-30",{"date":454,"type":40},"2024-01-30",{"date":456,"type":20},"2028-01-30",{"name":46,"class":47},5,{"id":460,"slug":461,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":466,"enrollmentInfo":467,"targetDuration":4,"studyType":21,"phases":469,"briefSummary":470,"conditions":471,"keywords":473,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":75},"100515194","psychoeducational-intervention-for-families-with-a-member-affected-by-major-depression-100515194","NCT05988333","Psychoeducational Intervention for Families With a Member Affected by Major Depression","The Efficacy of Psychoeducational Family Intervention for Individuals With Major Depression: a Randomized Controlled Trial","Inclusion Criteria:\n\n* diagnosis of major depression, according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition;\n* ability to provide informed consent;\n* presence of at least one contact per month with the psychiatric clinic for at least six months prior to recruitment;\n* cohabitation with at least one family member.\n\nExclusion Criteria:\n\n* moderate or severe cognitive deficits, physical illnesses preventing the participation to the sessions or if they were hospitalization in the two months prior the enrollment","65 Years",{"count":468,"type":20},384,[23],"Major depressive disorder (MDD) is the most common mental disorder. It can be a huge burden not only for the person affected by it, but also for his\u002Fher whole family. The goal of this clinical trial is to test the efficacy of a family supportive intervention called psychoeducational family intervention (PFI) compared to a brief informative intervention in families with a member affected by MDD. Families will participate in one of the two interventions for a period of 6 months more or less, and they will be asked to answer some questionnaires about how much MDD impacts on their everyday life and the patient's symptoms, in order to understand whether a more structured intervention such as PFI can be useful for families in order to better deal with this complicated illness.",[472],"Depressive Disorder, Major",[474,475,476,477],"depression","caregiver","family","psychoeducation","2024-04-16",{"date":480,"type":40},"2024-04-19",{"date":482,"type":40},"2023-09-27",{"date":484,"type":20},"2026-09",{"name":46,"class":47},{"id":487,"slug":488,"hasResults":11,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":11,"sex":16,"minAge":493,"maxAge":4,"enrollmentInfo":494,"targetDuration":496,"studyType":59,"phases":4,"briefSummary":497,"conditions":498,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":75},"100444798","monaldi-hospital-rhythm-registry-100444798","NCT05072119","Monaldi Hospital Rhythm Registry","Registry of Patients Underwent Cardiac Implanted Electronic Device Implantation at Monaldi Hospital","Inclusion Criteria:\n\n* All consecutive patients underwent PM\u002FICD\u002FILR implantation\n* Patient is willing and able to sign an authorization to use and disclose health information or an Informed Consent\n* Patient must be able to attend all required follow-up visits at the study center for at least 12 months\n\nExclusion Criteria:\n\n* No informed consent\n* Patient is participating in another clinical study that may have an impact on the study endpoint\n\nExclusion Criteria:\n\n* No informed consent","14 Years",{"count":495,"type":20},5000,"20 Years","The study is a prospective registry. Consecutive patients with indications of implant \u002F replacement or upgrade of pacemaker (PM), implantable cardioverter defibrillator (ICD), Implanted loop recorder (ILR) will be enrolled.\n\nThe primary objective of the study is to describe the clinical events during a long-term follow-up of non-selected population of patients implanted with an PM, ICD or ILR.",[499,500,501],"Pacemaker","ICD","Implanted Loop Recorder","2021-10-08",{"date":504,"type":40},"2021-10-15",{"date":506,"type":40},"2015-01-07",{"date":508,"type":20},"2050-01",{"name":46,"class":47},{"id":511,"slug":512,"hasResults":11,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":518,"enrollmentInfo":519,"targetDuration":4,"studyType":21,"phases":520,"briefSummary":522,"conditions":523,"keywords":525,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":75},"100321338","phase-4-insulin-pump-vs-multiple-daily-injections-of-insulin-and-glyco-metabolic-control-in-type-1-diabetic-patients-100321338","NCT03463564","Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients","Effects of Insulin Pump Versus Multiple Daily Injections of Insulin on Glycemic and Metabolic Control in Type 1 Diabetic Patients Transitioned to the Adult Center: the Management and Technology for Transition Study (METRO)","METRO","Inclusion Criteria:\n\n* T1DM for at least 12 months\n* persistent HbA1c levels ≥ 7.5% (58 mmol\u002Fmol) despite optimized education therapy,\n* recurrent severe hypoglycemic episodes or high glucose variability\n* willingness to wear the insulin pump\n\nExclusion Criteria:\n\n* previous use of insulin pump\n* pregnancy or planning to become pregnant in the next 2 years,\n* lack of ability to use the study devices\n* history of severe chronic diseases\n* recent or concomitant use of corticosteroids\n* drug or alcohol abuse\n* psychiatric complaints that interfere with the correct use of the devices","30 Years",{"count":232,"type":20},[521],"PHASE4","The transition from the Pediatric clinic to the adult care is a challenging period for young adults with type 1 diabetes, due to the high risk of poor glycemic control. Achieving the glycemic target without hypoglycemia and\u002For large glucose excursions is of paramount importance for type 1 diabetic patients, who have high variability of daily glucose levels . Both insulin pump therapy and multiple daily injections of insulin are recommended strategy to achieve glycemic control in type 1 diabetes; however, no studies investigated the effects of insulin pump vs insulin injections on glycol-metabolic outcomes in the transition phase. The aim of this study was to evaluate the effects of continuous subcutaneous insulin infusion (CSII) therapy, as compared with multiple daily injections of insulin (MDI), on glycemic and metabolic control, in young type 1 diabetic patients transitioned to the adult diabetes care.",[524],"Type 1 Diabetes Mellitus",[526,527,528,529,530,531],"type 1 diabetes","transition","CSII","MDI","glycemic control","glucose variability","2018-03-13",{"date":534,"type":40},"2018-03-15",{"date":536,"type":4},"2016-01",{"date":538,"type":20},"2026-12",{"name":46,"class":47},""]